-
公开(公告)号:US09175093B2
公开(公告)日:2015-11-03
申请号:US13857063
申请日:2013-04-04
Applicant: RINAT NEUROSCIENCE CORP. , PFIZER INC.
Inventor: Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Xiayang Qiu , Pavel Strop , Yuli Wang
IPC: A61K39/395 , C07K16/40 , A61K45/06 , A61K39/00
CPC classification number: C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
Abstract translation: 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型(PCSK9)结合的拮抗抗体,其抗原结合部分和适体。 还提供了针对肽的抗体,其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病(包括治疗高胆固醇血症)的治疗方法。
-
公开(公告)号:US10941216B2
公开(公告)日:2021-03-09
申请号:US15593259
申请日:2017-05-11
Applicant: PFIZER INC. , RINAT NEUROSCIENCE CORP.
Inventor: Pavel Strop , Magdalena Grazyna Dorywalska , Arvind Rajpal , David Shelton , Shu-Hui Liu , Jaume Pons , Russell Dushin
Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
-
公开(公告)号:US10138303B2
公开(公告)日:2018-11-27
申请号:US15351275
申请日:2016-11-14
Applicant: RINAT NEUROSCIENCE CORP.
Inventor: Weihsien Ho , Jaume Pons , Arvind Rajpal , Pavel Strop
Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号:US08586721B2
公开(公告)日:2013-11-19
申请号:US13680569
申请日:2012-11-19
Applicant: Pfizer Inc. , Rinat Neuroscience Corp.
Inventor: Vishwas Madhav Paralkar , Donna Marie Stone , Mei Li , Jaume Pons
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N15/70 , C12N15/85
Abstract: The present invention provides antibodies and fragments thereof that bind to Dkk-1 and, in particular, to humanized antibodies and fragments thereof that bind to Dkk-1 and, even more particularly to fully humanized antibodies and immunologically functional fragments that bind to Dkk-1. Also provided are antibodies and fragments thereof which compete with the binding of an anti-mouse Dkk-1 monoclonal antibody for binding to Dkk-1+ cells. Also provided are nucleic acids encoding anti-Dkk-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-Dkk-1 antibodies and fragments thereof. Also provided are methods of preparing the antibodies and fragments thereof of the invention. Also provided are bone anabolic agents. Pharmaceutical compositions comprising the antibodies or fragments thereof of the invention are also provided. Further provided are methods of treating diseases, conditions and disorders, such as bone disorders, which result in a loss of bone. Methods of treating or preventing a loss of bone mass, methods of inducing increased bone mass, and methods of inducing Wnt activity are also provided.
Abstract translation: 本发明提供了与Dkk-1结合的抗体及其片段,特别是结合Dkk-1的人源化抗体及其片段,更具体地,涉及与Dkk-1结合的完全人源化抗体和免疫功能片段 。 还提供了与抗小鼠Dkk-1单克隆抗体与Dkk-1 +细胞的结合竞争的抗体及其片段。 还提供了编码抗-Dkk-1抗体或其片段的核酸,以及掺入这些核酸用于重组表达抗-Dkk-1抗体及其片段的表达载体和宿主细胞。 还提供了制备本发明的抗体及其片段的方法。 还提供骨合成代谢剂。 还提供了包含本发明的抗体或其片段的药物组合物。 还提供了治疗导致骨丢失的疾病,病症和障碍(例如骨骼疾病)的方法。 还提供了治疗或预防骨量丧失的方法,诱导骨量增加的方法和诱导Wnt活性的方法。
-
公开(公告)号:US11008386B2
公开(公告)日:2021-05-18
申请号:US15622551
申请日:2017-06-14
Applicant: Rinat Neuroscience Corp.
Inventor: Jaume Pons , Arnon Rosenthal
Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
-
公开(公告)号:US09708398B2
公开(公告)日:2017-07-18
申请号:US14940710
申请日:2015-11-13
Applicant: RINAT NEUROSCIENCE CORP.
Inventor: Jaume Pons , Arnon Rosenthal
CPC classification number: C07K16/22 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
-
-
-
-
-